Like many other companies and institutions around the world, we are experiencing interference with some of our systems within the TNT network.
We are implementing remediation steps as quickly as possible. We have implemented operational contingencies to continue to complete collections from customers with scheduled stops. For customers who do not have a regular stop, collection should be arranged via our customer service centers.
Customers may experience delays in the transit of shipments, particularly inter-continental or non-EU European delivery, as we work to remediate our systems. Additionally, if customers do not have the facility for self-labeling, they may also experience delays.
We are not able to collect shipments of dangerous goods at this time.
We regret any inconvenience to our customers.
Latest from Almac
August 15th, 2018
Almac Group Soars up Ulster Business Top 100 Charts
Diagnostic Solutions for Biomarker-Driven Clinical Trials
August 6th, 2018
Almac Discovery, Elasmogen and Innovate UK Collaborate to Develop VNAR Based Oncology Platform
New temperature management strategy ensures GDP compliance and patient safety
Partnering to advance human healthExplore our locations
Brexit - a seamless solution
Timely assurance to you, our client, in relation to Brexit negotiations
Almac recognises that you need bespoke solutions to suit your needs. Only we can combine the expertise from our world leading range of specialised drug development services to support you across the full biopharmaceutical product lifecycle, from the preclinical stages through to commercialisation.
Almac Diagnostics is our stratified medicine business unit, specialising in biomarker driven clinical trials. Our global laboratories, in the UK and US, offer tailored solutions from discovery to commercialisation: biomarker discovery, assay development & validation, CDx development & commercialisation. Your clinical trial diagnostic partner.
Almac Discovery is a research driven, oncology business unit within Almac dedicated to the discovery and development of novel, innovative approaches to the treatment of cancer. We focus on early stage development and partner programmes with the pharmaceutical industry at the discovery to preclinical stage.